Evidence map›Paper›PMID 37647010›Full record

ArticleThe patient2023

Maximum Acceptable Risk Estimation Based on a Discrete Choice Experiment and a Probabilistic Threshold Technique.

Jorien Veldwijk, Rachael Lynn DiSantostefano, Ellen Janssen, Gwenda Simons, Matthias Englbrecht, Karin Schölin Bywall, Christine Radawski, Karim Raza, Brett Hauber, Marie Falahee

Open access · hybridAbstract read
In one paragraph

Article in The patient, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Comparing Discrete Choice Experiment with Swing Weighting to Estimate Attribute Relative Importance: A Case Study in Lung Cancer Patient Preferences.Medical decision making : an international journal of the Society for Medical Decision Making · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 5 countries.

Jorien VeldwijkSchool of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, 3000, Rotterdam, The Netherlands. veldwijk@eshpm.eur.nl.ORCID 0000-0003-4822-5068
Rachael Lynn DiSantostefanoJanssen Research & Development, Titusville, NJ, USA.
Ellen JanssenJanssen Research & Development, Titusville, NJ, USA.
Gwenda SimonsRheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
Matthias EnglbrechtFreelance Healthcare Data Scientist, Greven, Germany.
Karin Schölin BywallCentre for Research Ethics & Bioethics, Uppsala University, Uppsala, Sweden.
Christine RadawskiEli Lilly and Company, Indianapolis, IN, USA.
Karim RazaRheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
Brett Hauber *Pfizer, Inc., New York, NY, USA.
Marie Falahee *Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
Janssen (United States) · USUniversity of Birmingham · GBEli Lilly (United States) · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEPfizer (United States) · USSandwell & West Birmingham Hospitals NHS Trust · GBUniversity Medical Center Utrecht · NLUppsala University · SE

Funding

Innovative Medicines Initiative 115966
6 · The paper itself

Abstract

objectiveWe aimed to empirically compare maximum acceptable risk results estimated using both a discrete choice experiment (DCE) and a probabilistic threshold technique (PTT).

methodsMembers of the UK general public (n = 982) completed an online survey including a DCE and a PTT (in random order) measuring their preferences for preventative treatment for rheumatoid arthritis. For the DCE, a Bayesian D-efficient design consisting of four blocks of 15 choice tasks was constructed including six attributes with varying levels. The PTT used identical risk and benefit attributes. For the DCE, a panel mixed-logit model was conducted, both mean and individual estimates were used to calculate maximum acceptable risk. For the PTT, interval regression was used to calculate maximum acceptable risk. Perceived complexity of the choice tasks and preference heterogeneity were investigated for both methods.

resultsMaximum acceptable risk confidence intervals of both methods overlapped for serious infection and serious side effects but not for mild side effects (maximum acceptable risk was 32.7 percent-points lower in the PTT). Although, both DCE and PTT tasks overall were considered easy or very easy to understand and answer, significantly more respondents rated the DCE choice tasks as easier to understand compared with those who rated the PTT as easier (7-percentage point difference; p < 0.05).

conclusionsMaximum acceptable risk estimate confidence intervals based on a DCE and a PTT overlapped for two out of the three included risk attributes. More respondents rated the DCE as easier to understand. This may suggest that the DCE is better suited in studies estimating maximum acceptable risk for multiple risk attributes of differing severity, while the PTT may be better suited when measuring heterogeneity in maximum acceptable risk estimates or when investigating one or more serious adverse events.

Indexed as

Arthritis, RheumatoidChoice BehaviorPatient PreferenceAdultAgedBayes TheoremFemaleHumansMaleMiddle AgedRisk AssessmentSurveys and QuestionnairesUnited KingdomYoung Adult

Identifiers

PMID37647010
PMCPMC10570171
OpenAlexW4386271851

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.